1. Home
  2. CALC vs ALUR Comparison

CALC vs ALUR Comparison

Compare CALC & ALUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CALC
  • ALUR
  • Stock Information
  • Founded
  • CALC 2011
  • ALUR 2009
  • Country
  • CALC United States
  • ALUR United States
  • Employees
  • CALC 15
  • ALUR N/A
  • Industry
  • CALC Biotechnology: Pharmaceutical Preparations
  • ALUR
  • Sector
  • CALC Health Care
  • ALUR
  • Exchange
  • CALC Nasdaq
  • ALUR Nasdaq
  • Market Cap
  • CALC 22.9M
  • ALUR 22.8M
  • IPO Year
  • CALC N/A
  • ALUR N/A
  • Fundamental
  • Price
  • CALC $1.43
  • ALUR $2.50
  • Analyst Decision
  • CALC Strong Buy
  • ALUR Strong Buy
  • Analyst Count
  • CALC 3
  • ALUR 3
  • Target Price
  • CALC $16.33
  • ALUR $22.83
  • AVG Volume (30 Days)
  • CALC 22.6K
  • ALUR 89.4K
  • Earning Date
  • CALC 08-11-2025
  • ALUR 08-12-2025
  • Dividend Yield
  • CALC N/A
  • ALUR N/A
  • EPS Growth
  • CALC N/A
  • ALUR N/A
  • EPS
  • CALC N/A
  • ALUR N/A
  • Revenue
  • CALC N/A
  • ALUR $28,304,000.00
  • Revenue This Year
  • CALC N/A
  • ALUR N/A
  • Revenue Next Year
  • CALC N/A
  • ALUR $49.37
  • P/E Ratio
  • CALC N/A
  • ALUR N/A
  • Revenue Growth
  • CALC N/A
  • ALUR N/A
  • 52 Week Low
  • CALC $1.43
  • ALUR $2.15
  • 52 Week High
  • CALC $5.97
  • ALUR $39.91
  • Technical
  • Relative Strength Index (RSI)
  • CALC 32.78
  • ALUR 46.28
  • Support Level
  • CALC $1.48
  • ALUR $2.38
  • Resistance Level
  • CALC $1.79
  • ALUR $2.66
  • Average True Range (ATR)
  • CALC 0.12
  • ALUR 0.15
  • MACD
  • CALC -0.02
  • ALUR -0.02
  • Stochastic Oscillator
  • CALC 0.00
  • ALUR 38.83

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

About ALUR Allurion Technologies Inc.

Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.

Share on Social Networks: